Abstract
Statin-based drugs are the mainstay of therapy for coronary artery disease. Recent insights into the cellular mechanisms of this class of drugs suggest that modulation of nitric oxide synthesis contributes to their beneficial actions. These effects are independent of their lipid-lowering effects and result in enhanced nitric oxide release.
MeSH terms
-
Animals
-
Anticholesteremic Agents / pharmacology*
-
Endothelium, Vascular / drug effects*
-
Humans
-
Hypolipidemic Agents / pharmacology*
-
Lipid Metabolism
-
Lovastatin / analogs & derivatives
-
Lovastatin / pharmacology*
-
Models, Biological
-
Nitric Oxide Synthase / metabolism*
-
Nitric Oxide Synthase Type III
-
Oxidative Stress
-
Protein Processing, Post-Translational
-
Rats
Substances
-
Anticholesteremic Agents
-
Hypolipidemic Agents
-
Lovastatin
-
NOS3 protein, human
-
Nitric Oxide Synthase
-
Nitric Oxide Synthase Type III
-
Nos3 protein, rat